JANUMET XR (sitagliptin/metformin extended-release) Patient Assistance Program
Don’t let the high cost of brand specialty taxane chemotherapy disrupt your treatment. We help eligible patients access Jevtana (cabazitaxel) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey.
- Annual Re-certification And Refills Management
- Medicare Part D Patients Accepted
HIPAA Compliant
BBB Accredited
Secure Website
Key Takeaways:
- Jevtana (cabazitaxel) is FDA-approved in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing regimen. It is a second-generation taxane chemotherapy given by IV infusion every 3 weeks.
- Without assistance, Jevtana costs commonly run approximately $11,000–$13,500 per infusion.
- Through AffordMyPrescriptions, qualifying patients can access Jevtana for a flat $69.95 per month — our advocacy team manages the entire enrollment, refills, and renewal process.
- Generic cabazitaxel is now available in the U.S. at substantially lower cost. Other treatment options for metastatic CRPC after docetaxel include enzalutamide (Xtandi), abiraterone (Zytiga, generic available), radium-223 (Xofigo) for bone-predominant disease, lutetium-177-PSMA (Pluvicto) for PSMA-positive disease, and poly-ADP ribose polymerase inhibitors for BRCA-mutated disease.
What Is Jevtana Prescription Assistance Program?
The Jevtana Prescription Assistance Program is a manufacturer-sponsored initiative that provides Jevtana at little or no medication cost to qualifying patients based on income and insurance status. The program is designed for metastatic CRPC patients who are uninsured or underinsured, as well as Medicare beneficiaries.
Navigating the program on your own means dealing with eligibility verification, oncology coordination, prior-authorization documentation, infusion-center logistics, and renewal deadlines.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your enrollment, from initial application through ongoing infusion-coordination and re-certification.
Pharmacy Price Comparison
- Without assistance, brand Jevtana costs roughly $11,000–$13,500 per infusion. Generic cabazitaxel is much cheaper. A Patient Assistance Program is the meaningful path forward — if you qualify:
| Pharmacy(With Coupon) | PrIce (30-Day)* | You Save W/ Us |
|---|---|---|
| Walgreens (brand) | ~$13,000/dose | Save substantially |
| CVS Pharmacy (brand) | ~$13,500/dose | Save substantially |
| Walmart (brand) | ~$11,500/dose | Save substantially |
| Costco (brand) | ~$11,200/dose | Save substantially |
Generic cabazitaxel | ~$4,500/dose | Generic — lower |
*Just a heads-up — retail prices are estimates based on public data and vary by pharmacy. AffordMyPrescriptions Advocacy Service bypasses this by using drug manufacturer programs to secure your medication directly at no cost or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Jevtana Prescription Program?
The Patient Assistance Program is free to apply for and provides Jevtana at no medication cost if approved. Our $69.95/month service covers full advocacy. With generic cabazitaxel now available at lower cost, we’ll help your oncologist determine the best path.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for medication assistance programs.
We Advocate
Our specialists help gather documentation, complete applications, and coordinate with program providers.
Receive Medication
Once approved, you may receive your medication through the assistance program while we help manage ongoing paperwork and renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Jevtana:
Limitations of Coupons
- Prices fluctuate — savings aren’t guaranteed month-to-month
- Copay accumulators may prevent savings from counting toward deductible
- Coupon cards expire and require constant renewal
Still $11,000–$13,500/dose per month even with the best discount
- Can’t be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
- Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
- Medication supplied directly through the assistance program
- We manage all paperwork, refills, and annual renewals
- If denied, we explore alternative savings on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Jevtana assistance.
- You Are A U.S. Citizen Or Legal Resident
- You Have A Valid Jevtana Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured, Underinsured, Or A Medicare Part D Beneficiary
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Not sure if you qualify? Our pre-qualification check is completely free. If we can’t help, you won’t be charged.
Understanding Jevtana:
Jevtana (cabazitaxel) is a second-generation taxane chemotherapy used for metastatic castration-resistant prostate cancer (CRPC) after docetaxel failure. It was designed to overcome the P-glycoprotein-mediated efflux mechanism that contributes to docetaxel resistance.
How Jevtana Works:
Taxanes bind to and stabilize microtubules, preventing the dynamic reorganization required for mitosis, which leads to cell-cycle arrest and cell death. While docetaxel is the first-line taxane for metastatic CRPC, patients often develop resistance via P-glycoprotein efflux pumps. Cabazitaxel is a semi-synthetic taxane designed to be a poor substrate for these pumps, allowing it to remain effective in docetaxel-resistant cancer cells. When combined with prednisone, it produces a meaningful overall survival benefit compared to older treatments like mitoxantrone.
Form and use:
Jevtana is administered as an intravenous infusion over 1 hour every 3 weeks, with a typical dose of 25 mg/m² or 20 mg/m² depending on patient tolerability. It is given concurrently with oral prednisone at a dose of 10 mg daily throughout the treatment period. Premedication with an antihistamine, H2 blocker, and corticosteroid is required 30 minutes before the infusion to prevent severe hypersensitivity reactions. Additionally, G-CSF prophylaxis is often recommended for patients undergoing this regimen.
Generic availability:
Generic cabazitaxel is available in the United States at a substantially lower cost than the brand-name Jevtana. For post-docetaxel metastatic CRPC, other treatment alternatives include hormonal therapies like enzalutamide and abiraterone, as well as radium-223 for symptomatic bone metastases. Additionally, lutetium-177-PSMA is available for PSMA-positive disease, while various PARP inhibitors can be utilized for cases involving BRCA mutations or homologous recombination repair deficiencies.
Warnings:
Jevtana carries a boxed warning for severe and fatal neutropenia, requiring weekly complete blood counts during the first cycle and avoidance if neutrophil counts are too low. It also carries a boxed warning for severe hypersensitivity reactions, making proper premedication mandatory. Other significant warnings associated with the medication include severe gastrointestinal symptoms such as hemorrhage and perforation, renal failure, urinary disorders like cystitis, interstitial lung disease, hepatic impairment, and embryo-fetal toxicity.
FAQ (Frequently Asked Questions)
How Much Does Jevtana Cost Without Insurance?
Brand Jevtana costs approximately $11,000–$13,500 per infusion. Generic cabazitaxel is substantially cheaper. Through AffordMyPrescriptions, qualifying patients receive Jevtana at no medication cost — our $69.95 monthly fee covers full advocacy and program management.
Is Generic Cabazitaxel The Same As Brand Jevtana?
Yes. The FDA approves generic cabazitaxel as bioequivalent to brand Jevtana — same active ingredient at the same dose and concentration. Most oncologists are comfortable prescribing generic cabazitaxel. Most insurance plans prefer generic over brand.
Why Cabazitaxel After Docetaxel?
Most metastatic CRPC patients are treated with docetaxel chemotherapy at some point. Eventually, most patients develop docetaxel resistance — often through P-glycoprotein-mediated drug efflux. Cabazitaxel was designed to evade P-gp and remain effective in docetaxel-resistant cells. Clinical trials (TROPIC) showed cabazitaxel provides survival benefit in patients who have progressed on docetaxel.
Why The Prednisone?
Concurrent prednisone 10 mg/day is part of the standard cabazitaxel regimen for CRPC. Prednisone has its own modest anti-tumor activity in CRPC (suppresses adrenal androgens) and reduces some chemotherapy side effects. The combination was used in the registration trials.
What About PROSELICA — Is 20 Mg/m² Better Than 25 Mg/m²?
PROSELICA was a phase 3 non-inferiority trial showing 20 mg/m² cabazitaxel is non-inferior in survival to 25 mg/m² but with substantially less toxicity (neutropenia, febrile neutropenia diarrhea). Many oncologists now use 20 mg/m² as the starting dose, especially in older or frailer patients. The choice between 20 and 25 mg/m² is individualized.
Can I Get Jevtana Through The PAP If I Have Medicare?
Yes. Jevtana is typically billed through Medicare Part B (provider-administered IV infusion), which covers most of the cost; the PAP can help with copays or for patients without insurance.
What If My Application Is Denied?
If denied, we explore alternatives — switching to generic cabazitaxel (much cheaper), or other later-line metastatic CRPC therapies (Xtandi, generic abiraterone, radium-223, PSMA-targeted radioligand therapy, PARP inhibitors for BRCA+), the manufacturer’s copay program for commercially insured patients, or independent foundations such as the Prostate Cancer Foundation, ZERO Prostate Cancer, PAN Foundation, or HealthWell Foundation. If we cannot find a path, you won’t be charged our service fee.
Take Control of Your Medication Costs
If you are struggling with the high cost of Jevtana, our team may be able to help you access assistance programs — or guide you to generic cabazitaxel if it fits your situation. Check your eligibility today.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.